Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Kyle LaHucik

Senior Reporter

Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Catalent sells New Jersey plant to Belgian CDMO, plans moving HQ elsewhere

Exclusive: British startup raises $16M to find genes that rewind the epigenetic clock

FDA to reconsider removal of Lilly's GLP-1 drug from shortage list, a win for compounding pharmacies

Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Jasper shares rally as chronic hives drug scores in small, early trial

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome